COMMUNIQUÉS West-GlobeNewswire

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
07/05/2026
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, [...]
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
07/05/2026
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast - to - coast RLT manufacturing network – the largest in the US Expanded [...]
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
07/05/2026
Renewed agreement provides streamlined access to ENvue equipment and supplies across a network of more than 90 hospitals in 17 states TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc . (NASDAQ: FEED) (“ [...]
AskBio Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
07/05/2026
Durham, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Three oral and 3 poster presentations demonstrate progress of AskBio’s gene therapy research, development, and manufacturing activities Viralgen continues its pioneering [...]
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
07/05/2026
ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 [...]
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
07/05/2026
Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in heparin-induced thrombocytopenia (HIT) PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal [...]
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
07/05/2026
-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue with the FDA toward [...]
Stryker declares an $0.88 per share quarterly dividend
07/05/2026
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality
07/05/2026
Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospital, three HOPE [...]
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
07/05/2026
US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark expansion of company’s coast - to - coast RLT manufacturing network – the largest in the US Expanded [...]
InStride Health Sustains Outstanding Clinical Results in Third Annual Outcomes Report; Announces State Expansion Across East Coast
07/05/2026
97% of InStride patients demonstrate clinical improvement as company nearly doubled patient enrollment in 2025 ahead of continued state expansion BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- InStride Health , the leader in [...]
Tria Federal Unveils Integrated Solutions Platform and New Website
07/05/2026
Tria helps federal health agencies achieve their critical missions by navigating complex tradeoffs between cost, quality, and access to care ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Tria Federal has unveiled a [...]
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
07/05/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new [...]
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
07/05/2026
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory [...]
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
07/05/2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic [...]
UroGen Pharma to Present at Upcoming Investor Conferences
07/05/2026
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
07/05/2026
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved therapies [...]
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
07/05/2026
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its [...]
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
07/05/2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it [...]

Pages